The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
K

1L Therapy for T-ALL: What Are the AALL0434 vs. AALL1231 EFS/OS Outcomes? Is There More Gr4-5 Infectious Toxicity in AALL1231?

By ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases FEATURING Ken Byrd
By ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases FEATURING Ken Byrd
0 views
March 5, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
17:35
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

COVID-19 Coagulopathy: What Is Virchow’s Triad? What Are the VTE Rat…

Feat. P. Harris
18:31
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

COVID-19 Therapeutics: Remdesivir/Bamlanivimab/Casirivimab+Imdevimab…

Feat. K. Konrardy
15:40
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

COVID-19 & Hematologic Malignancies: What Is the Mortality Estim…

Feat. J. Leal
19:48
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

2021 Updates on Thrombosis: VTE & Recurrence, Use of DOACs in GI…

Feat. K. Halkidis
17:38
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

CAR-T & Experimental Therapeutics for AML: Is Allo-SCT the Only …

Feat. T. Lin
15:46
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

SCT for MDS: Do Older Patients With Advanced MDS Benefit From Allo-H…

Feat. A. Singh
05:21
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

HCT in MF: Is OS Better With Upfront JAKi vs. HCT? What Are the Outc…

Feat. A. Singh
09:23
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on HCT for AML: Are We Starting to Refer AML Patients Ear…

Feat. M. Mushtaq
07:01
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

Allogeneic Transplantation & AML Outcomes: What Is the Role of H…

Feat. M. Mushtaq
08:38
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on Myelofibrosis: What Are the Outcomes After Ruxolitinib…

Feat. A. Yacoub
07:44
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on CML Management: Does the TKI Choice Affect Survival? A…

Feat. A. Yacoub
09:26
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

1L Therapy for Ph- B-ALL: What Is Blinatumomab MRD Response & RF…

Feat. K. Byrd
09:20
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

1L Therapy for T-ALL: What Are the AALL0434 vs. AALL1231 EFS/OS Outc…

Feat. K. Byrd
06:36
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on Intensive Induction for AML: What Is the 5-Year Follow…

Feat. H. Male
11:45
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on Moderate-Intensity Chemo for AML: What Are the Remissi…

Feat. H. Male
11:54
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on MDS Management: What Are the Outcomes of Venetoclax fo…

Feat. B. Skikne
08:01
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

TP53 Mutations in MDS: Is Combination of Eprenetapopt + AZA Well-Tol…

Feat. B. Skikne
14:31
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

ASH Update on Higher-Risk MDS: Efficacy/Safety of Pevonedistat + Aza…

Feat. B. Skikne